https://p005091inhibitor.com/c....onnection-between-te
Whole-exome profiling uncovered ER (ESR1) mutations in 4 out of 7 patients (57.1%) who benefited from alternating 17-estradiol/AI therapy, markedly contrasting with the 2 out of 9 (22.2%) in those who did not experience clinical benefit. Tumor ESR1 mutations were identified in both patients who experienced objective responses to the initial 17-estradiol treatment. Exploring the efficacy of alternating 17-estradiol and AI thera
پسند
تبصرہ
بانٹیں
